Huw joined the OBN Board in April 2022. He has been CEO of Evgen Pharma PLC, a clinical stage cancer and inflammation company, since late 2020. In early 2021 Huw led the raise of £11m in a placing and open offer in a transformative deal for Evgen. In late 2022 He led a major out licensing deal between Evgen and Stalicla SA in neurodevelopmental disorders worth a potential $160.5m in milestone payments and a double-digit royalty. Most recently he was a non-executive director of Ixaka Ltd a cell and gene therapy company and Non-executive Chairman of Chronos Therapeutics Ltd in Oxford.

During his time at Chronos, Huw extracted the company from Oxford University, raised tens of millions in grant and equity finance and led Chronos’ acquisition of three early research programmes in brain disease from Shire PLC. He was surprised and pleased to have been awarded European CEO of the year 2016/17 for drug discovery by European CEO Magazine, alongside leaders in their sectors from Adidas, Unilever and Spotify.

Huw's previous posts include: Non-Executive Director, then rescue CEO, Ardana PLC; non–executive chairman of Ashbourne Pharmaceuticals; president Europe for NASDAQ listed CV Therapeutics Inc; SVP Europe, Elan Pharmaceuticals and various roles of increasing responsibility at SmithKline Beecham (GSK).

A native of south west Wales, Huw has a degree in pharmacology from Cardiff University and a PhD in neuropharmacology from the University of Birmingham. In addition to speaking at industry events as a speaker or panel member, he is occasionally called upon to comment on healthcare matters in Welsh on both S4C and Radio Cymru.

Huw is a passionate rugby union supporter, enjoys SCUBA diving, cycling and wine appreciation.